Breaking news on multiple sclerosis
Mr. Lube Canada Supports The Multiple Sclerosis Society Of Canada And MS Awareness Month Through Its Founder's Day Campaign published
Wed, 07 May 2008 05:00:00 PDT
On Saturday, May 10th, 2008 Mr. Lube Canada will be supporting the Multiple Sclerosis (MS) Society of Canada and MS Awareness Month by donating $5 from every oil change purchase at Mr. Lube locations across the country. Canada has one of the highest rates of MS in the world and women are diagnosed with the disease three times more frequently than men. These are two stark facts that serve as motivation for those who work to end the disease and primary reasons for Mr.
Multiple Sclerosis, A Communication Breakdown - Research Profile From The Canadian Institutes Of Health Research (CIHR) published
Wed, 07 May 2008 03:00:00 PDT
Multiple sclerosis (MS) is, essentially, a failure to communicate. In a person with MS, the immune system has run amok, destroying the protective myelin coat that surrounds nerve cells. Without this myelin, messages cannot travel between the brain and the body as quickly as they can in a healthy person, and the exposed nerve cells begin to die.
Multiple Sclerosis Activity May Be Affected By Prozac published
Sat, 03 May 2008 00:00:00 PDT
A new study published in the Journal ofNeurology Neurosurgery and Psychiatry finds that Prozac, acommonly prescribed antidepressant, may be an agent in slowingdown the disease process of the relapsing remitting form of multiplesclerosis (MS).Multiple sclerosis is an autoimmune disease where the immune systemattacks the central nervous system. In the relapsing remitting form,new symptoms occur in discrete attacks.
Multiple Sclerosis Awareness Month: MS Society Reflects On 60 Years Of Progress, Canada published
Fri, 02 May 2008 03:00:00 PDT
Since 1948, the Multiple Sclerosis Society of Canada has led Canada to become one of the world's premier destinations for MS research and has improved hundreds of thousands lives through client care. These are just two reflections to consider during a May, MS Awareness Month.
Merck Serono And ZymoGenetics Initiate Atacicept Phase 2 Clinical Trial In Relapsing Multiple Sclerosis published
Fri, 02 May 2008 03:00:00 PDT
ZymoGenetics, Inc. (NASDAQ:ZGEN), announced that its development partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has initiated a Phase 2 clinical trial to evaluate the safety and efficacy of atacicept in patients with relapsing multiple sclerosis (RMS). "Patients with multiple sclerosis need more treatment options," said Nicole Onetto, M.D., Senior Vice President and Chief Medical Officer of ZymoGenetics.
DNA Vaccines May Offer Hope In MS published
Fri, 25 Apr 2008 02:00:00 PDT
Authors from the VA North Texas Health Care System Neurology Section and the Department of Neurology at the University of Texas Southwestern Medical Center at Dallas have highlighted the potential benefits for DNA-based vaccine administration in patients with multiple sclerosis (MS).
MS Society Comments On Stem Cells Story published
Thu, 24 Apr 2008 03:00:00 PDT
Dr Laura Bell from the MS Society said: "These are exciting times for MS research. Ten years ago there were no drugs to treat MS, but today there are a range of therapies available and a dozen more in late stage clinical trials. We're putting millions into MS research and very much hope that the new avenues we are exploring - including stem cells - will bring about major advances in the next ten years.
Registry Will Track Multiple Sclerosis To Help Combat The Disease, USA published
Thu, 24 Apr 2008 03:00:00 PDT
Congressmen Michael C. Burgess, M.D. (R-Texas) and Russ Carnahan (D-Missouri) introduced bi-partisan legislation to create a national registry to house information about Americans living with Multiple Sclerosis (MS.) A national registry would allow for future planning of health care needs, detect changes in health practices, assess disease burden, promote advocacy, and support a wide range of research initiatives.
Accelerated Cure Project For Multiple Sclerosis Is One Thousand Steps Closer To A Cure For MS published
Thu, 24 Apr 2008 00:00:00 PDT
Accelerated Cure Project for Multiple Sclerosis, a national nonprofit organization, announced that they have completed their initial drive to collect one thousand blood and data samples to build the largest openly accessible, multi-disciplinary repository ever assembled for use in Multiple Sclerosis (MS) research. "This is a major milestone for the Accelerated Cure Project", says Art Mellor, founder of the Accelerated Cure Project.
New Campaign Launched During MS Week published
Tue, 22 Apr 2008 02:00:00 PDT
The MS Society has launched this week's MS Week 2008 with a series of new adverts featuring images and words of people with multiple sclerosis (MS).The four new adverts encourage people living with the condition to explore the help that is out there, whether through the MS Society's branch network, self management courses, through online support forums, or via personalised care.
Potential MS Therapy Advanced By Minnesota Partnership published
Mon, 21 Apr 2008 02:00:00 PDT
A production laboratory founded by the Minnesota Partnership has transferred its first potential therapy - a medication for multiple sclerosis - to a processing plant in Minnesota. This step will complete purification of material to fully enable translation from preclinical to clinical development.
Idera Pharmaceuticals Presents Data From Study Of Toll-Like Receptor Antagonist In Preclinical Model Of Multiple Sclerosis published
Mon, 21 Apr 2008 01:00:00 PDT
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), announced the presentation of data from studies evaluating a Toll-Like Receptor (TLR) antagonist in a preclinical model of multiple sclerosis (MS). The presentation entitled "Studies of Oligonucleotide-Based Antagonists of TLR9 in a Mouse Model of Experimental Autoimmune Encephalomyelitis" (Abstract #2049) was made during the 60th Annual Meeting of the American Academy of Neurology being held in Chicago, IL, April 12-19, 2008.
Genentech And Biogen Idec Announce Top-Line Results From A Phase II/III Clinical Trial Of Rituxan In Primary-Progressive Multiple Sclerosis published
Mon, 21 Apr 2008 00:00:00 PDT
Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced that a Phase II/III study of Rituxan® (rituximab) for primary-progressive multiple sclerosis (PPMS) did not meet its primary endpoint as measured by the time to confirmed disease progression during the 96-week treatment period. Genentech and Biogen Idec will continue to analyze the study results and will submit the data for presentation at an upcoming medical meeting.
Germany: 'History Of MS' Short Film Now Available published
Sun, 20 Apr 2008 03:00:00 PDT
The German Multiple Sclerosis (MS) Society (DMSG) has worked with MS researchers, including Professor Jürg Kesselring (Chefarzt Neurology Rehabilitation Centre Hospital Valens, Switzerland) and Professor Peter Rieckmann (Chair for MS Research, Director of the MS Program of the University of British Columbia and Vancouver Coastal Health, Canada) to create 'Multiple Sclerosis - a journey through time'.
Reykjavik Conference 2008 - "Living Independently With Multiple Sclerosis" - Topic Of Next EMSP Conference Planned In Reykjavik, 22- 25 May, 2008 published
Sun, 20 Apr 2008 01:00:00 PDT
The event will take place in Reykjavik in Iceland and is intended for MS member organisations, medical experts, rehabilitation specialists and social support professionals. There will also be an update on the ongoing campaign to implement the "European Code of Good Practice" into national and regional level.
Successful Patient Advocacy Work In Slovakia - "The Association Of Young People With MS" In Slovakia Makes Changes Happen published
Sat, 19 Apr 2008 02:00:00 PDT
Together with Dr Lubica Prochazkova - chief doctor of Neurological section for Multiple Sclerosis in Slovakia and involded in the Association - they succeeded in cancelling the age restriction of 45 which prevented MS patients to access DMDs in Slovakia. There is no age restriction any more in Slovakia for having Interferons being prescribed.
Report Of Latest EMSP Conference, Noordwijk, November 2007 Reflects Progress Made In The Endorsement Process Of The "Code" And Consensus Papers published
Sat, 19 Apr 2008 01:00:00 PDT
The Noordwijk Workshop was organised to focus on the development of lobby strategies and tools to implement the "Code" on national level. Having obtained political endorsement of the "Code" and its Consensus Papers by the European Institutions, the Noordwijk objective for EMSP (European Multiple Scleroris Platform) was to translate what has been achieved on European level into national legislation and daily practice.
New European Multiple Sclerosis Platform Project: Roundtable For National Endorsement Of The EMSP "Code" And Consensus Papers published
Fri, 18 Apr 2008 13:00:00 PDT
Since 2003 - year of the EP resolution - EMSP (European Multiple Scleroris Platform) has been pursuing an important advocacy work focused on health inequalities in the European Union and beyond. The launch of the "Code of Good Practice" in 2007 has been a major milestone in the bid to raise awareness of Multiple Sclerosis and its impact on people's lives. Nevertheless MS remains under-diagnosed and sub-optimally treated in many European countries.
Disappointing Trials Results For Sativex, UK published
Fri, 18 Apr 2008 05:00:00 PDT
GW Pharmaceuticals, which makes Sativex - an oral spray containing a cannabis extract - has released disappointing results of a trial testing the drug's benefits in treating pain in people with multiple sclerosis (MS). The study involved 339 people experiencing neuropathic pain due to MS who have achieved inadequate pain relief with existing therapies.
Potential In Yeast For Selecting Lou Gehrig's Disease Drugs published
Fri, 18 Apr 2008 02:00:00 PDT
Researchers from the University of Pennsylvania School of Medicine are developing a novel approach to screen for drugs to combat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, using yeast cells. In recent months a number of mutations have been found in a disease protein called TDP-43, which is implicated in ALS and certain types of frontotemporal dementia (FTD).
Xanthus' Symadex Reverses Disease In Preclinical Mouse Models Of Multiple Sclerosis published
Fri, 18 Apr 2008 02:00:00 PDT
Xanthus Pharmaceuticals, Inc. presented data demonstrating that SymadexTM, a selective FLT3 inhibitor, acted to reverse disease in mouse models of both acute and chronic multiple sclerosis. Biomarkers of macrophage and dendritic cells showed a significant correction back towards the baseline levels found in healthy control animals. The results were presented in a poster session by Stephen J. Karlik, Ph.D.
Early Treatment With COPAXONE(R) Significantly Delayed Progression To Clinically Definite Multiple Sclerosis published
Fri, 18 Apr 2008 02:00:00 PDT
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced new results from the PreCISe study, which demonstrated that early treatment with COPAXONE® (glatiramer acetate injection) significantly reduced the risk of developing clinically definite multiple sclerosis (CDMS) by 45 percent compared to placebo (hazard ratio 0.55, p=0.0001). These data were presented as late-breaking science at the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago.
Opexa Therapeutics Presents Tovaxin Phase I/II Data At The American Academy Of Neurology 60th Annual Meeting published
Thu, 17 Apr 2008 06:00:00 PDT
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, announced that Brian Loftus, M.D.
Stay Active With The MS Competition - UK published
Thu, 17 Apr 2008 03:00:00 PDT
Regular, moderate exercise is now recognised as an important element in maintaining general health and well being. In the past, people with MS were advised to avoid exertion. It was felt that as many people with MS experienced fatigue and found their symptoms worsened when hot, it was best to avoid activities that could be seen as tiring.
New Data Show Treatment Of Multiple Sclerosis (MS) With AVONEX® (interferon Beta-1a) Enhances Quality Of Life published
Thu, 17 Apr 2008 01:00:00 PDT
Results from a one-year prospective, observational study conducted to determine the impact of beginning treatment with AVONEX on MS patients' overall quality of life (QoL) were announced today. The data showed that patients receiving treatment with AVONEX experienced statistically significant improvements in QoL, as measured by the EuroQol questionnaire (EQ-5D), compared to baseline.
)
|
|
